Supernus Pharmaceuticals, Inc. (SUPN)
SUPN moved a median of -0.09% 30 minutes after news, and +0.11% by the close. How SUPN actually reacts to news — the realized, point-in-time move the market made, measured across 504 labeled events over the last three years with zero look-ahead.
SUPN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 503 |
| 30-min | -0.09% | 42% | 504 |
| 60-min | -0.01% | 49% | 504 |
| to close | +0.11% | 53% | 500 |
| Middle 50% of SUPN reactions | -0.68% to +0.56% |
|---|---|
| Median reaction (30-min) | -0.09% |
| Measured reactions | 504 |
Half of all Supernus Pharmaceuticals, Inc. news events land between -0.68% and +0.56% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SUPN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 20 | +0.17% | 50% | -0.80% |
| Analyst downgrades | 23 | +0.45% | 52% | +1.22% |
| Rating reiterations | 16 | -0.08% | 50% | +0.08% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SUPN ranks against every other measured name →
That’s how SUPN usually reacts — get an email when it moves on news →Email me when SUPN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SUPN's baseline. Nothing else.
Recent SUPN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEFA14A SUPERNUS PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.61% | -0.07% | |
| Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.02% | -1.18% | |
| Form DEFM14A SUPERNUS PHARMACEUTICALS | SEC filing · Form DEFM14A | SEC EDGAR | +0.21% | -1.59% | |
| Supernus Pharmaceuticals to Participate in September Investor Conferences | Press release | GlobeNewswire | -1.50% | -1.32% | |
| Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD | Press release | GlobeNewswire | -0.72% | +0.89% | |
| SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.72% | +0.89% | |
| Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +1.29% | — | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.30% | -8.00% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Aug 01 | SEC filing · Form 8-K | SEC EDGAR | +1.30% | -8.00% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +1.30% | -8.00% | |
| Form DEFA14A SUPERNUS PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +1.30% | -8.00% | |
| Supernus Announces Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.30% | -8.00% | |
| Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale | Press release | GlobeNewswire | +1.30% | -8.00% | |
| SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.52% | -0.80% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | +1.68% | |
| Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026 | Press release | GlobeNewswire | +0.13% | +1.68% | |
| Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD | Press release | GlobeNewswire | -0.17% | -0.49% | |
| Form S-8 SUPERNUS PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +0.04% | -0.47% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | -0.04% | |
| Supernus Pharmaceuticals to Participate in June Investor Conferences | Press release | GlobeNewswire | -0.84% | +0.47% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: May 17 | SEC filing · Form 8-K | SEC EDGAR | -0.66% | +1.44% | |
| Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference | Press release | GlobeNewswire | -0.01% | +1.61% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.40% | +1.54% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | +1.54% | |
| Supernus Announces First Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.40% | +1.54% | |
| Form ARS SUPERNUS PHARMACEUTICALS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.58% | -0.35% | |
| Form DEF 14A SUPERNUS PHARMACEUTICALS For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | -0.58% | -0.35% | |
| Form DEFA14A SUPERNUS PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.58% | -0.35% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +1.34% | -0.71% | |
| Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026 | Press release | GlobeNewswire | +1.34% | -0.71% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +0.44% | -0.69% | |
| Form 10-K SUPERNUS PHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.09% | +0.53% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +1.22% | -0.32% | |
| Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +1.22% | -0.32% | |
| Supernus Pharmaceuticals to Participate in March Investor Conferences | Press release | GlobeNewswire | +0.35% | +4.61% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | +1.99% | |
| Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 | Press release | GlobeNewswire | +0.30% | +1.99% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | +0.39% | +0.66% | |
| Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada | Press release | Business Wire | +0.47% | -3.38% | |
| Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference | Press release | GlobeNewswire | +0.46% | +0.76% | |
| Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +0.06% | -0.77% | |
| Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London | Press release | GlobeNewswire | +0.63% | — | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.03% | -1.60% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +9.80% | +5.39% | |
| Supernus Announces Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +9.80% | +5.39% | |
| Form 8-K SUPERNUS PHARMACEUTICALS For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | -0.10% | |
| Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 | Press release | GlobeNewswire | +0.19% | -0.10% | |
| Form 8-K/A SUPERNUS PHARMACEUTICALS For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +0.97% | |
| Supernus Pharmaceuticals to Participate in September Investor Conferences | Press release | GlobeNewswire | -0.54% | +0.67% | |
| Form 10-Q SUPERNUS PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.11% | +8.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SUPN section they belong to.
Where else SUPN is measured.
SUPN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Celyad Oncology SA - American Depositary Shares (CYAD) | 504 | 0.00% | 41% |
| DELMAR PHARMACEUTICALS (DMPI) | 504 | -0.13% | 38% |
| CORINDUS VASCULAR ROBOTICS INC (CVRS) | 503 | -0.65% | 37% |
| Teligent, Inc. (TLGT) | 502 | -0.17% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Supernus Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled SUPN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 504 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of SUPN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SUPN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.